30 closest matches · ranked by relevance
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome · Chronic Fatigue Syndrome · Myalgic Encephalomyelitis
Primary: Change in Peak Oxygen Uptake (Peak VO2) Between the First and Second iCPET — 13.3; -40.3; 111.8 mL/min — p=0.043
Chronic Fatigue Syndrome
Primary: Cardiopulmonary Exercise Test (CPET) - ATVO2rel — 16.0; 10.6 mL/kg/min
Chronic Fatigue Syndrome · Cognitive Impairments
Primary: Change in BRIEF-A — 21.38; 3.36 Scores on a scale — p=.005
Myalgic Encephalomyelitis · Chronic Fatigue Syndrome
Primary: Total Daily Symptom Score (TDSS) — 29.5; 28.7; 29.2; 31.3 units on a scale — p=0.011
Chronic Fatigue Syndrome
Primary: Change in Fatigue Impact Scale at 6 Weeks — -32.6; -1.5 units on a scale — p=< 0.05
Pain · Fatigue
Primary: Short Form 36 (SF-36) Physical Component Summary (PCS) — 36.2; 39.0 Scores on a scale — p=0.487
Multiple Sclerosis
Primary: Change From Baseline in Fatigue Levels — 50.98; 56.88; 57.87 score on a scale
Chronic Fatigue Syndrome
Primary: Changes in Frequency and Severity of CDC-based CFS Symptoms — 0.29; 0.12; 0.49; 0.05 Units on a scale
Gulf War · Fatigue · Pain
Primary: Short Form McGill Pain Questionnaire (SF-MPQ-2) Total Score — 69.2; 64.9; 62.3; 55.5 score on scale
Fibromyalgia
Primary: Change in Ratio of Choline/ Creatine (CHO/CR) in the Brain From Baseline to 3 Hrs Post-endotoxin Administration — -.0021; -.0058 ratio
Multiple Sclerosis
Primary: Change From Baseline in Subscale Scores of the Fatigue Impact Scale — -3.74; -1.22; -4.24; -1.11 units on a scale — p=<0.05
Multiple Sclerosis, Relapsing-Remitting
Primary: Fatigue at 28 Weeks — 56.50; 29.00; 55.00; 40.00 score on a scale
Widespread Chronic Pain
Primary: Development of Chronic Widespread Pain Assessed by Questionnaire — 69; 77 Participants
Multiple Sclerosis · Fatigue · Physical Activity
Primary: Daily Average Fatigue Intensity Score — 3.9; 4.4; 3.2; 2.3 units on a scale
Fatigue Syndrome, Chronic
Primary: Change From Baseline in Multidimensional Fatigue Inventory (MFI)--General Fatigue Subscale Score — -3.3; -1.8 units on a scale — p=0.23
Mitochondrial Diseases
Primary: Average TSST-induced Elevation in Cortisol — 37.44; 33.86; 42.83; 45.42 ng*min/mL
Migraine Disorders
Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants
Fatigue in Multiple Sclerosis
Primary: Modified Fatigue Impact Scale (MFIS) Score — 40.6; 41.3; 39.0; 38.6 score on a scale
Multiple Sclerosis
Primary: Change in the Modified Fatigue Impact Scale (MFIS) Score — -15.2; -16.0; -17.3 score on a scale — p=0.3451
Multiple Sclerosis · Fatigue
Primary: Intervention Acceptability — 4.36; 4.64; 4.68 Units on a scale
Fibromyalgia
Primary: Pain Intensity Using Numeric Rating Scale — 5.12; 6.36; 6.62 units on a scale — p=0.045
Multiple Sclerosis · Fatigue
Primary: Modified Fatigue Inventory Scale (MFIS) — 46.5; 55.2; 54.3; 45.1 units on a scale — p=0.9489
Post COVID-19 Condition · Long COVID
Primary: Change From Baseline to Week 13 in PROMIS Fatigue Score (T-Score) — 69.9; 69.4; -25.4; -25.8 T-Score — p=0.9851
Fibromyalgia · Neurocognition
Primary: Visual Analogue Scale for Pain — 59.4; 68.6; 58.5; 66.2 mm
Q Fever · Fatigue Syndrome, Chronic · Coxiella Infection
Primary: Checklist Individual Strength (CIS) — 31.6; 40.8; 37.8 score on a scale
Neurofibromatosis 1
Primary: Mitochondrial Respiration Efficiency (as Measured by OCR). — 67.7167; 53.7000; 73.3358; 68.5789 picomole/minute — p=<0.01
Progressive Multiple Sclerosis · Fatigue
Primary: Number of Adverse Events Reported Since Baseline Visit That Are Related to N-acetyl Cysteine. — 12; 6 adverse events
Fibromyalgia · Myofascial Pain Syndrome · Muscular Diseases
Primary: Functional Disability Inventory — 25.78; 24.10; 25.96; 21.83 score on a scale
Heart Failure
Primary: Maximal Voluntary Quadriceps Force [% Change From Baseline] — -30; -5 percentage change
Fibromyalgia · Mitochondrial Diseases · Movement Disorders
Primary: Heart Rate Variability (Time Domain) — 0.92; 0.83 msec/msec — p=0.77